114 / 464
SUNDAY 7 MAY 2017
114
SCIENTIFIC PROGRAMME
| Programme and Exhibition Guide
14:45 > Modern biomarkers for therapeutic strategy: radiation dose or volume
modification
Speaker: M. Krause (Germany)
SP-0291
15:10 > The changing role of head and neck surgeon in HPV-positive
oropharyngeal squamous cell carcinoma, or do we still need surgery?
Speaker: C. Simon (Switzerland)
SP-0292
15:35 > Radiation de-escalation strategies in HPV-positive squamous cell
carcinoma
Speaker: J. Giralt (Spain)
SP-0293
SYMPOSIUMWITH PROFFERED PAPERS
Costs and value of radiotherapy innovations: how to assess
14:45 - 16:00 | SCHUBERT `
After some examples of Health Technology Assessment (HTA) in the broader cancer
care context, specific challenges related to assessing radiotherapy interventions and
implementing HTA recommendations into the daily radiation oncology practice, will
be discussed.
Thereafter, the necessary components of economic appraisals will be examined:
what are radiotherapy costs and how to define them; how to evaluate the outcome
of the treatments we deliver and the expected benefit to our patients. To illustrate
the latter, the ESMO-Magnitude of Clinical Benefit scale will be presented and it will
be discussed how the development of such a tool may be applied in the context of
radiation oncology.
Chair: Y. Lievens (Belgium)
Co-chair: J. Novotny (Czech Republic)
14:45 > Health Technology Assessment: what’s in a word?
A. Aggarwal (UK)
SP-0294
15:06 > Radiotherapy costs: the good, the bad and the ugly
L. Perrier (France)
SP-0295
15:27 > A critical quality appraisal of studies estimating the cost of radiotherapy
N. Defourny (Belgium)
OC-0296
15:37 > Method of development of ESMO Magnitude of Clinical Benefit
applicable for radiotherapy?
E.G.E. De Vries (The Netherlands)
SP-0297